| Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron JM Carreño, H Alshammary, J Tcheou, G Singh, AJ Raskin, H Kawabata, ... Nature 602 (7898), 682-688, 2022 | 453 | 2022 |
| Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study A Ozonoff, J Schaenman, ND Jayavelu, CE Milliren, CS Calfee, CB Cairns, ... EBioMedicine 83, 2022 | 33 | 2022 |
| Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B. 1.617. 2, B. 1.351, B. 1.1. 7+ E484K and a sub-variant of C. 37 JM Carreno, H Alshammary, G Singh, A Raskin, F Amanat, A Amoako, ... medRxiv, 2021.07. 21.21260961, 2021 | 23 | 2021 |
| Safety and immunogenicity analysis of a Newcastle disease virus (NDV-HXP-S) expressing the spike protein of SARS-CoV-2 in sprague dawley rats J Tcheou, A Raskin, G Singh, H Kawabata, D Bielak, W Sun, ... Frontiers in Immunology 12, 791764, 2021 | 17 | 2021 |
| Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results … S Ponce-de-León, M Torres, LE Soto-Ramírez, JJ Calva, ... medRxiv, 2022 | 16 | 2022 |
| Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico S Ponce-de-León, M Torres, LE Soto-Ramírez, JJ Calva, ... npj Vaccines 8 (1), 67, 2023 | 9 | 2023 |
| An In Vitro Microneutralization Assay for Influenza Virus Serology F Cuevas, H Kawabata, F Krammer, JM Carreño Current Protocols 2 (7), e465, 2022 | 9 | 2022 |
| SARS-CoV-2 spike-binding antibody longevity and protection from reinfection with antigenically similar SARS-CoV-2 variants J Kubale, C Gleason, JM Carreño, K Srivastava, G Singh, A Gordon, ... MBio, 2022 | 6 | 2022 |
| Group PPS JM Carreño, H Alshammary, J Tcheou, G Singh, A Raskin, H Kawabata, ... Srivastava K., Sordillo EM, Bajic G., van Bakel H., Simon V., Krammer F …, 2021 | 5 | 2021 |
| An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination JM Carreño, A Raskin, G Singh, J Tcheou, H Kawabata, C Gleason, ... Science Translational Medicine 15 (683), eabo2847, 2023 | 3 | 2023 |
| Correction: An In Vitro Microneutralization Assay for Influenza Virus Serology F Cuevas, H Kawabata, F Krammer, JM Carreño Current Protocols 2 (9), e567, 2022 | | 2022 |
| The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines JM Carreño, A Raskin, G Singh, J Tcheou, H Kawabata, C Gleason, ... medRxiv, 2022.01. 25.22269808, 2022 | | 2022 |
| Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study (preprint) A Ozonoff, J Schaenman, ND Jayavelu, CE Milliren, CS Calfee, CB Cairns, ... | | 2022 |
| Activity of convalescent and vaccine serum against a B. 1.1. 529 variant SARS-CoV-2 isolate (preprint) JM Carreno, H Alshammary, J Tcheou, G Singh, A Raskin, H Kawabata, ... | | 2021 |
